An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder.
OBJECTIVE
The aim of this study was to examine the efficacy, safety, and tolerability of paroxetine in adolescents with unipolar major depression.


METHODS
Two hundred eighty-six (286) adolescents with unipolar major depression were randomly assigned to receive either paroxetine or placebo for 12 weeks.


RESULTS
The proportion of Montgomery-Asberg Depression Rating Scale (MADRS) responders (at least 50% reduction from baseline) for paroxetine and placebo were similar and not statistically different at endpoint (p = 0.702). A similar result was obtained for change from baseline on the Kiddie-Schedule for Affective Disorders and Schizophrenia for School- Age Children (K-SADS-L) depression subscale. Among secondary endpoints, only a significantly higher Clinical Global Impression-Improvement (CGI-I) response rate was reported in paroxetine-treated patients versus placebo (69.2% versus 57.3%; p = 0.045). In general, results differed by age, with patients older than 16 years demonstrating a greater response to active treatment. This age group also reported more adverse experiences (AEs) relative to placebo than younger adolescents. Overall, paroxetine was generally well tolerated (11% discontinued owing to an AE versus 7% of placebo-treated patients). A post hoc analysis of AEs related to suicidal behavior suggested a greater incidence of these events for paroxetine than for placebo (4.4% versus 2.1%); however, this difference was not statistically significant (odds ratio, 2.15, 95% Confidence Interval 0.45, 10.33; p = 0.502).


CONCLUSIONS
No statistically significant differences were observed for paroxetine compared with placebo on the two prospectively defined primary efficacy variables. Paroxetine at 20-40 mg/day administered over a period of up to 12 weeks was generally well tolerated.
University of Cape Town Medical School/Groote Schuur Hospital, Cape Town, South Africa. berard@intekom.co.za
Ray
R
Berard
Regan
R
Fong
David J
DJ
Carpenter
Christine
C
Thomason
Christel
C
Wilkinson
D000293:Adolescent; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D038622:Internationality; D016015:Logistic Models; D008297:Male; D017374:Paroxetine / Q000627:therapeutic use*; D011446:Prospective Studies; D016037:Single-Blind Method
D017374:Paroxetine